20th Annual Diabetes Conference Online Course
Date of Release
07/01/2019
Period of Validity
07/01/2019 - 07/01/2022
Welcome to the 20th Annual Diabetes Conference Online Enduring Material Activities. There are five continuing education modules focusing on current treatments for diabetes complications.
Instructions for completing the modules and claiming CME:
- Review each module’s CME information document.
- Register for each module. You will receive a confirmation email which also includes instructions.
- Once the Thank You page appears, click on the link to begin the activity (a new window opens to the activity home page).
- Click on the correct module title to watch the video recording.
- Complete the attestation/evaluation and claim credit:
- Use the tab at the top to go back to the Thank You page and the Continue to the Post Test button appears.
- Complete the Attestation and Evaluation, claim credit and then download/print your certificate.
David Herrmann, MD & Alicia Gotcsik, CO, CPED
Program Description
This module includes a discussion of the clinical features and diagnosis of diabetic distal symmetrical polyneuropathy (DSN). The consideration of the differential diagnosis of DSPN, the appropriate work-up and management options will be covered. The second speaker will explain the mechanisms of injury/symptoms of complications of the neuropathic foot in the setting of ulceration, Charcot Arthropathy and amputation. Orthotic treatment protocols for the insensate foot including diabetic wounds, Charcot Arthropathy and partial foot amputations will be reviewed.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Diagnose diabetic distal symmetric polyneuropathy (DSPN) and differentiate it from other forms of diabetic neuropathy and other causes of distal symmetric polyneuropathy.
- Learn about management options for DSPN and treatment outcomes.
- Have a better understanding of treatment protocols for complications of the diabetic foot.
- Help understand the mechanisms of injury of the insensate foot/ offer prevention tips to patients.
Module 1 CME Information
Register Here For Module 1
___________________________________________________________________________________________________________________________________________________________
George Bakris, MD, MA
Program Description
Fewer people with diabetes today are progressing to dialysis compared to 30 years. Moreover, the rate of annual decline in kidney function is slower by 70% compared to 1980. Lastly, newer classes of drugs shown to lower glucose have also shown a further slowing of CKD progression in diabetes.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Describe the latest statistics regarding diabetic kidney disease progression.
- Identify newer guideline approaches to achieve BP and glucose control to slow CKD progression.
Module 2 CME Information
Register Here For Module 2
___________________________________________________________________________________________________________________________________________________________
Lloyd Axelrod, MD
Program Description
This module will review the causes, pathogenesis, consequences and management of hypoglycemia in diabetic patients.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Recognize the clinical manifestations of hypoglycemia in diabetic patients including hypoglycemia unawareness.
- Modify management to prevent and, when present, treat hypoglycemia in diabetic patients.
Module 3 CME Information
Register Here For Module 3
___________________________________________________________________________________________________________________________________________________________
David DiLoreto, MD, PhD
Program Description
This update will summarize the historical treatments of diabetic retinopathy, what the current treatment for diabetic retinopathy currently are, and what the future may hold.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Describe the laser treatment of diabetic retinopathy.
- Explain the intravitreal pharmacologic treatment of diabetic retinopathy.
Module 4 CME Information
Register Here For Module 4
___________________________________________________________________________________________________________________________________________________________
Cecilia Low Wang, MD
Program Description
Cardiovascular disease accounts for much of the mortality and significant morbidity in patients with type 2 diabetes. Data supporting cardiovascular risk reduction from diabetes drugs had not been convincing until the 2008 FDA Guidance mandating robust cardiovascular safety data for new glucose-lowering drugs led to large cardiovascular outcome trials that have demonstrated cardiovascular risk reduction with 2 new classes of diabetes drugs. We now have new diabetes drugs with indications for cardiovascular risk reduction in patients with established cardiovascular disease, with new promise for lowering cardiovascular events and mortality significantly for our patients. I will describe the highlights of key trials now incorporated into recent statements and guidelines from leading professional societies, with practical management recommendations.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Describe key aspects of the recent history of diabetes drug approval by the FDA.
- Outline a practical approach to selection of glucose-lowering drugs in patients with cardiovascular disease.
Module 5 CME Information
Register Here For Module 5